These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16440134)

  • 1. Improvement of lung function in patients with systemic sclerosis after 6 months cyclophosphamide pulse therapy.
    Ostojic P; Damjanov N
    Clin Rheumatol; 2006 Nov; 25(6):819-21. PubMed ID: 16440134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term effects of immunosuppressive therapy on lung function in scleroderma patients.
    Pavlov-Dolijanovic S; Vujasinovic Stupar N; Zugic V; Ostojic P; Zekovic A; Zivanovic Radnic T; Jeremic I; Tadic I
    Clin Rheumatol; 2018 Nov; 37(11):3043-3050. PubMed ID: 30143960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose prednisolone and bolus cyclophosphamide in interstitial lung disease associated with systemic sclerosis: a prospective open study.
    Wanchu A; Suryanaryana BS; Sharma S; Sharma A; Bambery P
    Int J Rheum Dis; 2009 Sep; 12(3):239-42. PubMed ID: 20374353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial.
    Burt RK; Shah SJ; Dill K; Grant T; Gheorghiade M; Schroeder J; Craig R; Hirano I; Marshall K; Ruderman E; Jovanovic B; Milanetti F; Jain S; Boyce K; Morgan A; Carr J; Barr W
    Lancet; 2011 Aug; 378(9790):498-506. PubMed ID: 21777972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of micronutrient antioxidants (alpha-tocopherol and ascorbic acid) on skin thickening and lung function in patients with early diffuse systemic sclerosis.
    Ostojic P; Damjanov N
    Rheumatol Int; 2011 Aug; 31(8):1051-4. PubMed ID: 20309694
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic sclerosis: comparison of efficacy of oral cyclophosphamide and azathioprine on skin score and pulmonary involvement-a retrospective study.
    Poormoghim H; Rezaei N; Sheidaie Z; Almasi AR; Moradi-Lakeh M; Almasi S; Andalib E
    Rheumatol Int; 2014 Dec; 34(12):1691-9. PubMed ID: 24801572
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function.
    van den Hombergh WMT; Simons SO; Teesselink E; Knaapen-Hans HKA; van den Hoogen FHJ; Fransen J; Vonk MC
    Clin Rheumatol; 2018 Oct; 37(10):2715-2722. PubMed ID: 29987427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma.
    Hoyles RK; Ellis RW; Wellsbury J; Lees B; Newlands P; Goh NS; Roberts C; Desai S; Herrick AL; McHugh NJ; Foley NM; Pearson SB; Emery P; Veale DJ; Denton CP; Wells AU; Black CM; du Bois RM
    Arthritis Rheum; 2006 Dec; 54(12):3962-70. PubMed ID: 17133610
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclophosphamide pulse regimen in the treatment of alveolitis in systemic sclerosis.
    Giacomelli R; Valentini G; Salsano F; Cipriani P; Sambo P; Conforti ML; Fulminis A; De Luca A; Farina G; Candela M; Generini S; De Francisci A; Tirri E; Proietti M; Bombardieri S; Gabrielli A; Tonietti G; Cerinic MM
    J Rheumatol; 2002 Apr; 29(4):731-6. PubMed ID: 11950014
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral cyclophosphamide improves pulmonary function in scleroderma patients with fibrosing alveolitis: experience in one centre.
    Beretta L; Caronni M; Raimondi M; Ponti A; Viscuso T; Origgi L; Scorza R
    Clin Rheumatol; 2007 Feb; 26(2):168-72. PubMed ID: 16614793
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide for Systemic Sclerosis-related Interstitial Lung Disease: A Comparison of Scleroderma Lung Study I and II.
    Volkmann ER; Tashkin DP; Sim M; Li N; Khanna D; Roth MD; Clements PJ; Hoffmann-Vold AM; Furst DE; Kim G; Goldin J; Elashoff RM
    J Rheumatol; 2019 Oct; 46(10):1316-1325. PubMed ID: 30770517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of therapeutic response before and during i.v. cyclophosphamide pulse therapy for interstitial lung disease in systemic sclerosis: A longitudinal observational study.
    Sumida H; Asano Y; Tamaki Z; Aozasa N; Taniguchi T; Toyama T; Takahashi T; Ichimura Y; Noda S; Akamata K; Saigusa R; Miyazaki M; Kuwano Y; Yanaba K; Yoshizaki A; Sato S
    J Dermatol; 2018 Dec; 45(12):1425-1433. PubMed ID: 30289572
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
    Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
    Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease.
    Pakas I; Ioannidis JP; Malagari K; Skopouli FN; Moutsopoulos HM; Vlachoyiannopoulos PG
    J Rheumatol; 2002 Feb; 29(2):298-304. PubMed ID: 11842824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
    Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
    Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts.
    Volkmann ER; Tashkin DP; Sim M; Li N; Goldmuntz E; Keyes-Elstein L; Pinckney A; Furst DE; Clements PJ; Khanna D; Steen V; Schraufnagel DE; Arami S; Hsu V; Roth MD; Elashoff RM; Sullivan KM;
    Ann Rheum Dis; 2019 Jan; 78(1):122-130. PubMed ID: 30409830
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravenous cyclophosphamide for interstitial lung disease associated to systemic sclerosis: results with an 18-month long protocol including a maintenance phase.
    Airò P; Danieli E; Rossi M; Frassi M; Cavazzana I; Scarsi M; Grottolo A; Franceschini F; Zambruni A
    Clin Exp Rheumatol; 2007; 25(2):293-6. PubMed ID: 17543156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic sclerosis and interstitial lung disease: a pilot study using pulse intravenous methylprednisolone and cyclophosphamide to assess the effect on high resolution computed tomography scan and lung function.
    Griffiths B; Miles S; Moss H; Robertson R; Veale D; Emery P
    J Rheumatol; 2002 Nov; 29(11):2371-8. PubMed ID: 12415594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cyclophosphamide for scleroderma lung disease: a systematic review and meta-analysis.
    Poormoghim H; Moradi Lakeh M; Mohammadipour M; Sodagari F; Toofaninjed N
    Rheumatol Int; 2012 Aug; 32(8):2431-44. PubMed ID: 21691743
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease.
    Silver RM; Warrick JH; Kinsella MB; Staudt LS; Baumann MH; Strange C
    J Rheumatol; 1993 May; 20(5):838-44. PubMed ID: 8336309
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.